Immunoactivation blood perfusion filter for the treatment of malignant tumors
The invention provides a way of producing a natural immunologically active state in a person by subjecting him to an apheresis procedure with bioincompatible biomaterials for about one hour. To safely control the immunological shock induced by this procedure, the person is put under general anesthesia for about six hours, including the apheresis time and at least an additional five hours thereafter. This immunological activation is useful for treating malignant tumors and diseases related to immunosuppression, such as AIDS. The invention also provides for the use of an apheresis column containing a blood perfusion filter with bioincompatible materials for treating malignant tumors and infectious diseases.
1. A method of treating a disease in a patient comprising:
(a) providing an apheresis system including a blood perfusion filter comprising at least one bioincompatible material;
(b) connecting the patient's blood circulation with the apheresis system such that the patient's blood passes through the blood perfusion filter before reentering the patient's body;
(c) placing the patient under general anesthesia and providing physiological support to the patient;
(d) circulating the patient's blood through the apheresis system for about one hour; and
(e) keeping the patient under general anesthesia for at least 5 hours after circulating the patient's blood through the apheresis system,
wherein circulating the patient's blood through the blood perfusion filter creates a lymphocyte dominant state in the patient's immune system.
2. The method of claim 1 , wherein the disease is a malignant tumor.
3. The method of claim 1 , wherein the disease is an infectious disease.
4. The method of claim 3 , wherein the infectious disease is acquired immune deficiency syndrome (AIDS) or hepatitis.
5. The method of claim 1 , wherein the apheresis system further comprises an air chamber and/or a warming bag.
6. The method of claim 1 , wherein the bioincompatible material is a cotton or a silk.
7. The method of claim 6 , wherein the cotton is selected from Egyptian cotton, Australian cotton, and Pakistani cotton.
8. The method of claim 6 , wherein the silk is selected from Japanese silk and Kanton silk.
9. The method of claim 1 , wherein the bioincompatible material is biolized.
10. The method of claim 9 , wherein the bioincompatible material is biolized with formaldehyde or glutaraldehyde.
11. The method of claim 1 , wherein the patient is a human patient.
12. The method of claim 1 , wherein the patient is a non-human animal.
13. The method of claim 1 , wherein the general anesthesia is ketamine.
14. The method of claim 1 , wherein the physiological support is chosen from at least one of maintenance of blood pressure and maintenance of blood gas levels.
15. The method of claim 1 , further comprising the step of administering an anticoagulant to the patient before circulating the patient's blood through the apheresis system.
16. The method of claim 15 , wherein the anticoagulant is heparin.
17. The method of claim 1 , wherein the patient's blood is circulated through the apheresis system at a rate of about 100 to 200 ml/minute.
18. A method of treating a disease in a patient comprising:
(a) connecting an apheresis system including a blood perfusion filter comprising at least one bioincompatible material to a patient's blood circulation such that the patient's blood can pass through the blood perfusion filter before reentering the patient's body; and
(b) administering a general anesthetic for anesthetizing the patient during use of the apheresis system and for at least 5 hours following that use for treating a disease in a patient,
wherein use of the apheresis system creates a lymphocyte dominant state in the patient's immune system.
19. A kit for treating a disease in a patient comprising:
(a) an apheresis system including a blood perfusion filter comprising at least one bioincompatible material, and
(b) a general anesthetic for anesthetizing the patient during use of the apheresis system and for at least 5 hours following that use for treating a disease in a patient,
wherein use of the apheresis system creates a lymphocyte dominant state in the patient's immune system.